4 ms·
Following the status quo path will likely result in significantly more people dying. It's a gamble either way, and if you want to argue that the risk of a first
by bobcostas55 6y ago
Following the status quo path will likely result in significantly more people dying. It's a gamble either way, and if you want to argue that the risk of a first-doses-first approach is not worth the risk, then quantify your reasoning and explain exactly how many extra deaths you're willing to accept instead of these platitudes about paths.
- curiousllama 6y agoYou can't ask me to quantify my reasoning and then throw out wild unsubstantiated claims out like: > Following the status quo path will likely result in significantly more people dying Besides, the clinical trials _are_ quantified. The issue is we don't have data for the potential changes. Armchair speculation of "maybe half will work" != data
- mhb 6y agoNo. But we can ask the FDA to justify its reasoning by sharing their modeling of the expected value of QALY for different courses of actions. It's ridiculous for them to spit out a proclamation like this without providing a framework for the decision other than "has not been tested".